February 5, 2021
Alex Kentsis, a Josie Robertson Investigator from 2013 to 2018 and now the director of the Tow Center for Developmental Oncology, is the senior author of a study that shows how a protein called MYB can be targeted, suggesting a new approach for drugs that could treat a range of cancers, especially myeloid leukemias, in both children and adults.
December 28, 2020
New findings from the lab of Josie Robertson Investigator Samuel Bakhoum help explain why some tumors do not respond to immunotherapy—suggesting new ways to sensitize them to immunotherapy.
December 21, 2020
Josie Robertson Investigator Piro Lito contributed to new research showing that a drug called sotorasib (AMG 510) slowed or stopped cancer growth in many people with advanced cancer containing a version of the mutant KRAS protein called KRAS-G12C.
December 21, 2020
Josie Robertson Investigators Elli Papaemmanuil, Karuna Ganesh, and Tuomas Tammela played key roles in some of the most consequential breakthroughs of the year.
October 26, 2020
Josie Robertson Investigator Elli Papaemmanuil is studying clonal hematopoiesis, an age-related blood condition that increases the risk of blood cancer.
October 6, 2020
Josie Robertson Investigator Thomas Norman has received a National Institutes of Health Director’s New Innovator Award, which supports highly innovative research from early-stage investigators whose creativity and research has the potential to produce a major impact.
September 20, 2020
Josie Robertson Investigator Piro Lito is a senior author of the landmark research paper in the New England Journal of Medicine.
August 3, 2020
Josie Robertson Investigator Elli Papaemmanuil was the lead scientist on a study that has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia.
July 23, 2020
Josie Robertson Investigator Tuomas Tammela and his colleagues have identified an unusual cell state that emerges early in tumor evolution and supports a cancer’s ability to outwit chemotherapy.
June 29, 2020
Josie Robertson Investigator Yael David delivers her MSK Science Spotlight lecture on June 29, 2020.
May 27, 2020
A study led by Josie Robertson Investigator Barry Taylor and fellow computational oncologist Ed Reznik showed that nearly a quarter of all tumors have two different mutations in the same gene that contribute to the formation of an individual cancer.
May 4, 2020
Josie Robertson Investigator Andrea Schietinger delivers the Louise and Allston Boyer Young Investigator Award for Basic Research award lecture as part of MSK Science Spotlight.
MSK News, Spring 2020
A study led by Josie Robertson Investigator Barry Taylor and cancer geneticist Michael Berger led to an algorithm that helps determine where in the body a tumor originated.
January 13, 2020
Josie Robertson Investigator Karuna Ganesh was the first author on a paper presenting evidence that the ability of cancers to metastasize to other organs is dependent upon their ability to coopt natural wound-healing pathways.
October 2, 2019
A phase II trial led by Eli Diamond, David Hyman, and Josie Robertson Investigator Omar Abdel-Wahab led to a breakthrough treatment for adults with histiocytic disorders.
September 16, 2019
Josie Robertson Investigator Omar Abdel-Wahab and his colleagues in the Human Oncology and Pathogenesis Program (HOPP) analyzed data from MSK-IMPACTTM to show how the alteration of the XPO1 protein could cause cancer.
Josie Robertson Investigator Thomas Vierbuchen’s experience as a cancer patient reinforced his conviction that basic research is fundamental to the fight against cancer.
April 18, 2019
The laboratory of Josie Robertson Investigator Daniel Bachovchin is working toward a better understanding of pyroptosis, which could pave the way for new therapies for infectious disease, cancer, and autoimmune disorders.
March 20, 2019
Josie Robertson Investigator Yael David and her colleagues in the Sloan Kettering Institute have linked a type of protein damage called glycation to cancer and other diseases.
February 27, 2019
Josie Robertson Investigator Karuna Ganesh has brought a passion for seeking answers to fundamental scientific questions to her focus on understanding metastasis.
A look inside the lab of Josie Robertson Investigator and Medical Oncologist Karuna Ganesh.
The lab of Josie Robertson Investigator Samuel Bakhoum conducts research on chromosomal instability and its role in how cancer forms, spreads, and resists drugs.
January 4, 2019
The Cancer Genome Atlas has profoundly increased our understanding of the molecular basis of cancer. Josie Robertson Investigator Nikolaus Schultz was involved with the project from the beginning.
Josie Robertson Investigator Tuomas Tammela discusses his path to becoming a cancer researcher and how it led to the focus of his lab: to develop ways to reduce heterogeneity in tumors.
A look inside the lab of Josie Robertson Investigator and Cancer Biologist Tuomas Tammela.
October 4, 2018
Josie Robertson Investigator Samuel Bakhoum has received the 2018 National Institutes of Health Director’s Early Independence Award, which is given to exceptional scientists who have contributed significant work in biomedical research.
Chemical biologist Daniel Bachovchin studies the cellular signals that control immune responses. He says his guiding principle is that “the truth is always the most interesting possible result.”
Inside the lab of Josie Robertson Investigator and Chemical Biologist Daniel Bachovchin.
Tumor immunologist and Josie Robertson Investigator Andrea Schietinger studies why immune cells sometimes fail to fight cancer—and what can be done about it.
September 19, 2018
Josie Robertson Investigator Samuel Bakhoum and his colleagues are looking for ways to make checkpoint inhibitor drugs more effective. One tactic is by making cancer cells more visible to the immune system.
Large Study Pinpoints Genetic Changes Underlying Drug Resistance in the Most Common Type of Breast Cancer
September 10, 2018
Josie Robertson Investigator Barry Taylor and Physician-scientist David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO), were key collaborators on a study of hormone-resistant breast cancer tumors.
July 18, 2018
Josie Robertson Investigator Barry Taylor led a collaborative team of researchers who found that a genetic state called whole-genome doubling is more common than expected and is associated with worse outcomes in people with cancer.
July 18, 2018
Josie Robertson Investigator Omar Abdel-Wahab studies the process called splicing in an effort to develop a new treatment for blood cancers.
June 26, 2018
Josie Robertson Investigator Richard White, an expert in melanocytes and melanoma, studies zebrafish to determine whether the area surrounding a cancer cell can influence its fate.
June 19, 2018
Josie Robertson Investigator Omar Abdel-Wahab, a physician-scientist in the Human Oncology and Pathogenesis Program, studies the role of epigenetics in blood cancers.
June 14, 2018
Richard White, a physician-scientist in the Cancer Biology and Genetics Program at SKI, discovered that melanomas preferentially grow near adipose (fat) tissue and eagerly eat up the abundant fats, also called lipids, found there.
Josie Robertson Investigator Yael David focuses her research on epigenetics—the study of how proteins, small molecules, and other factors lying above the genome can influence which genes in a cell are expressed.
A look inside the lab of Josie Robertson Investigator and Chemical Biologist Yael David.
January 17, 2018
Josie Robertson Investigator Samuel Bakhoum was the lead author of a study that could guide treatment strategies to lock cancer from spreading.
Cancer Immunologist Andrea Schietinger of Sloan Kettering Institute Honored with Prestigious NIH Director’s New Innovator Award
Josie Robertson Investigator Andrea Schietinger was awarded for her groundbreaking work in immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy.
Working with xenografts in mice, Josie Robertson Investigator Piro Lito and his colleagues found that a combination of three targeted drugs was effective at preventing drug resistance in certain cancer cells.